755-nm picosecond laser plus topical 20% azelaic acid compared to topical 20% azelaic acid alone for the treatment of melasma: a randomized, split-face and controlled trial
Purpose: Melasma remains a refractory skin condition that needs to be actively explored. Azelaic acid has been used for decades as a topical agent to improve melasma through multiple mechanisms, however, there is a lack of research on its combination with laser therapy. This study evaluated the effe...
Gespeichert in:
| Veröffentlicht in: | Lasers in medical science 2024-04, Vol.39 (1), p.113-113, Article 113 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 113 |
|---|---|
| container_issue | 1 |
| container_start_page | 113 |
| container_title | Lasers in medical science |
| container_volume | 39 |
| creator | Lai, Dihui Cheng, Shaowei Zhou, Shaona Hao, Jianchun Chen, Hongguang Jia, Kang Liu, Hongmei Cui, Yong |
| description | Purpose: Melasma remains a refractory skin condition that needs to be actively explored. Azelaic acid has been used for decades as a topical agent to improve melasma through multiple mechanisms, however, there is a lack of research on its combination with laser therapy. This study evaluated the effectiveness of isolated treatment with topical 20% azelaic acid and its combination with 755-nm picosecond laser in facial melasma patients. Methods: A randomized, evaluator-blinded, controlled study was conducted on 30 subjects with facial melasma in a single center from October 2021 to April 2022. All subjects received topical 20% azelaic acid cream (AA) for 24 weeks, and after 4 weeks, a hemiface was randomly assigned to receive 755-nm picosecond (PS) laser therapy once every 4 weeks for 3 treatments. Treatment efficacy was determined by mMASI score evaluations, dermoscopic assessment, reflectance confocal microscopy (RCM) assessments and patient’s satisfaction assessments (PSA). Results: Treatment with 20% azelaic acid, with or without picosecond laser therapy, significantly reduced the hemi-mMASI score (
P
|
| doi_str_mv | 10.1007/s10103-024-04052-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3046511320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3046511320</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-95ad9b62346d1ce54a545d6c487859eb643df988ff7c9c9d3443c00de8ed68dc3</originalsourceid><addsrcrecordid>eNp9kcuKFTEQhoMozszRF3AhARFmYTTpXLp7djJ4gwE3Cu5CnaRae0g6bZJeOM_kQ5qZM14QdFVF5av_L_IT8kjw54Lz_kURXHDJeKcYV1x3bLxDjoWSmhmuPt39oz8iJ6Vcci56I-R9ciQHo42R4ph877VmS6Tr7FJBlxZPAxTMdA1boTW1OQTa8acUrjDA7Ci42VOX4goZfSP-DUFIC9IpZVq_IK0ZoUZcKk0TjQ0rEc4o0AyLT3G-Qv-MljXMlU3gkLZpc1lqTiFc--QZwgNyb4JQ8OFt3ZGPr199OH_LLt6_eXf-8oI52ZnKRg1-3JtOKuOFQ61AK-2NU0M_6BH3Rkk_jcMwTb0b3eilUtJx7nFAbwbv5I6cHnTXnL5uWKqNc3EYAiyYtmIlV0YLITve0Cd_oZdpy0u77obqO2Hal-9Id6BcTqVknOya5wj5mxXcXmdpD1nalqW9ydKObenxrfS2j-h_rfwMrwHyAJT2tHzG_Nv7P7I_AJgHqiI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3046721661</pqid></control><display><type>article</type><title>755-nm picosecond laser plus topical 20% azelaic acid compared to topical 20% azelaic acid alone for the treatment of melasma: a randomized, split-face and controlled trial</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Lai, Dihui ; Cheng, Shaowei ; Zhou, Shaona ; Hao, Jianchun ; Chen, Hongguang ; Jia, Kang ; Liu, Hongmei ; Cui, Yong</creator><creatorcontrib>Lai, Dihui ; Cheng, Shaowei ; Zhou, Shaona ; Hao, Jianchun ; Chen, Hongguang ; Jia, Kang ; Liu, Hongmei ; Cui, Yong</creatorcontrib><description>Purpose: Melasma remains a refractory skin condition that needs to be actively explored. Azelaic acid has been used for decades as a topical agent to improve melasma through multiple mechanisms, however, there is a lack of research on its combination with laser therapy. This study evaluated the effectiveness of isolated treatment with topical 20% azelaic acid and its combination with 755-nm picosecond laser in facial melasma patients. Methods: A randomized, evaluator-blinded, controlled study was conducted on 30 subjects with facial melasma in a single center from October 2021 to April 2022. All subjects received topical 20% azelaic acid cream (AA) for 24 weeks, and after 4 weeks, a hemiface was randomly assigned to receive 755-nm picosecond (PS) laser therapy once every 4 weeks for 3 treatments. Treatment efficacy was determined by mMASI score evaluations, dermoscopic assessment, reflectance confocal microscopy (RCM) assessments and patient’s satisfaction assessments (PSA). Results: Treatment with 20% azelaic acid, with or without picosecond laser therapy, significantly reduced the hemi-mMASI score (
P
< 0.0001) and resulted in higher patient satisfaction. Improvements in dermoscopic and RCM assessments were observed in both sides of the face over time, with no difference between the two sides. RCM exhibited better dentritic cell improvement in the combined treatment side. No patients had serious adverse effects at the end of treatment or during the follow-up period. Conclusion: The additional use of picosecond laser therapy showed no clinical difference except for subtle differences detected by RCM assessments.
The study was registered in the Chinese Clinical Trial Registry (ChiCTR2100051294; 18 September 2021).</description><identifier>ISSN: 1435-604X</identifier><identifier>ISSN: 0268-8921</identifier><identifier>EISSN: 1435-604X</identifier><identifier>DOI: 10.1007/s10103-024-04052-9</identifier><identifier>PMID: 38656631</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Acids ; Administration, Topical ; Adult ; Assessments ; Combined Modality Therapy ; Combined treatment ; Confocal microscopy ; Dentistry ; Dermatologic Agents - administration & dosage ; Dermatologic Agents - therapeutic use ; Dicarboxylic Acids - administration & dosage ; Dicarboxylic Acids - therapeutic use ; Female ; Humans ; Lasers ; Lasers, Solid-State - therapeutic use ; Low-Level Light Therapy - methods ; Male ; Medicine ; Medicine & Public Health ; Melanosis - radiotherapy ; Melanosis - therapy ; Middle Aged ; Optical Devices ; Optics ; Original Article ; Patient Satisfaction ; Patients ; Photonics ; Quantum Optics ; Single-Blind Method ; Skin diseases ; Therapy ; Treatment Outcome</subject><ispartof>Lasers in medical science, 2024-04, Vol.39 (1), p.113-113, Article 113</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-95ad9b62346d1ce54a545d6c487859eb643df988ff7c9c9d3443c00de8ed68dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10103-024-04052-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10103-024-04052-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38656631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lai, Dihui</creatorcontrib><creatorcontrib>Cheng, Shaowei</creatorcontrib><creatorcontrib>Zhou, Shaona</creatorcontrib><creatorcontrib>Hao, Jianchun</creatorcontrib><creatorcontrib>Chen, Hongguang</creatorcontrib><creatorcontrib>Jia, Kang</creatorcontrib><creatorcontrib>Liu, Hongmei</creatorcontrib><creatorcontrib>Cui, Yong</creatorcontrib><title>755-nm picosecond laser plus topical 20% azelaic acid compared to topical 20% azelaic acid alone for the treatment of melasma: a randomized, split-face and controlled trial</title><title>Lasers in medical science</title><addtitle>Lasers Med Sci</addtitle><addtitle>Lasers Med Sci</addtitle><description>Purpose: Melasma remains a refractory skin condition that needs to be actively explored. Azelaic acid has been used for decades as a topical agent to improve melasma through multiple mechanisms, however, there is a lack of research on its combination with laser therapy. This study evaluated the effectiveness of isolated treatment with topical 20% azelaic acid and its combination with 755-nm picosecond laser in facial melasma patients. Methods: A randomized, evaluator-blinded, controlled study was conducted on 30 subjects with facial melasma in a single center from October 2021 to April 2022. All subjects received topical 20% azelaic acid cream (AA) for 24 weeks, and after 4 weeks, a hemiface was randomly assigned to receive 755-nm picosecond (PS) laser therapy once every 4 weeks for 3 treatments. Treatment efficacy was determined by mMASI score evaluations, dermoscopic assessment, reflectance confocal microscopy (RCM) assessments and patient’s satisfaction assessments (PSA). Results: Treatment with 20% azelaic acid, with or without picosecond laser therapy, significantly reduced the hemi-mMASI score (
P
< 0.0001) and resulted in higher patient satisfaction. Improvements in dermoscopic and RCM assessments were observed in both sides of the face over time, with no difference between the two sides. RCM exhibited better dentritic cell improvement in the combined treatment side. No patients had serious adverse effects at the end of treatment or during the follow-up period. Conclusion: The additional use of picosecond laser therapy showed no clinical difference except for subtle differences detected by RCM assessments.
The study was registered in the Chinese Clinical Trial Registry (ChiCTR2100051294; 18 September 2021).</description><subject>Acids</subject><subject>Administration, Topical</subject><subject>Adult</subject><subject>Assessments</subject><subject>Combined Modality Therapy</subject><subject>Combined treatment</subject><subject>Confocal microscopy</subject><subject>Dentistry</subject><subject>Dermatologic Agents - administration & dosage</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Dicarboxylic Acids - administration & dosage</subject><subject>Dicarboxylic Acids - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Lasers</subject><subject>Lasers, Solid-State - therapeutic use</subject><subject>Low-Level Light Therapy - methods</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanosis - radiotherapy</subject><subject>Melanosis - therapy</subject><subject>Middle Aged</subject><subject>Optical Devices</subject><subject>Optics</subject><subject>Original Article</subject><subject>Patient Satisfaction</subject><subject>Patients</subject><subject>Photonics</subject><subject>Quantum Optics</subject><subject>Single-Blind Method</subject><subject>Skin diseases</subject><subject>Therapy</subject><subject>Treatment Outcome</subject><issn>1435-604X</issn><issn>0268-8921</issn><issn>1435-604X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcuKFTEQhoMozszRF3AhARFmYTTpXLp7djJ4gwE3Cu5CnaRae0g6bZJeOM_kQ5qZM14QdFVF5av_L_IT8kjw54Lz_kURXHDJeKcYV1x3bLxDjoWSmhmuPt39oz8iJ6Vcci56I-R9ciQHo42R4ph877VmS6Tr7FJBlxZPAxTMdA1boTW1OQTa8acUrjDA7Ci42VOX4goZfSP-DUFIC9IpZVq_IK0ZoUZcKk0TjQ0rEc4o0AyLT3G-Qv-MljXMlU3gkLZpc1lqTiFc--QZwgNyb4JQ8OFt3ZGPr199OH_LLt6_eXf-8oI52ZnKRg1-3JtOKuOFQ61AK-2NU0M_6BH3Rkk_jcMwTb0b3eilUtJx7nFAbwbv5I6cHnTXnL5uWKqNc3EYAiyYtmIlV0YLITve0Cd_oZdpy0u77obqO2Hal-9Id6BcTqVknOya5wj5mxXcXmdpD1nalqW9ydKObenxrfS2j-h_rfwMrwHyAJT2tHzG_Nv7P7I_AJgHqiI</recordid><startdate>20240424</startdate><enddate>20240424</enddate><creator>Lai, Dihui</creator><creator>Cheng, Shaowei</creator><creator>Zhou, Shaona</creator><creator>Hao, Jianchun</creator><creator>Chen, Hongguang</creator><creator>Jia, Kang</creator><creator>Liu, Hongmei</creator><creator>Cui, Yong</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7SP</scope><scope>7U5</scope><scope>8FD</scope><scope>FR3</scope><scope>H8D</scope><scope>K9.</scope><scope>L7M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20240424</creationdate><title>755-nm picosecond laser plus topical 20% azelaic acid compared to topical 20% azelaic acid alone for the treatment of melasma: a randomized, split-face and controlled trial</title><author>Lai, Dihui ; Cheng, Shaowei ; Zhou, Shaona ; Hao, Jianchun ; Chen, Hongguang ; Jia, Kang ; Liu, Hongmei ; Cui, Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-95ad9b62346d1ce54a545d6c487859eb643df988ff7c9c9d3443c00de8ed68dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Administration, Topical</topic><topic>Adult</topic><topic>Assessments</topic><topic>Combined Modality Therapy</topic><topic>Combined treatment</topic><topic>Confocal microscopy</topic><topic>Dentistry</topic><topic>Dermatologic Agents - administration & dosage</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Dicarboxylic Acids - administration & dosage</topic><topic>Dicarboxylic Acids - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Lasers</topic><topic>Lasers, Solid-State - therapeutic use</topic><topic>Low-Level Light Therapy - methods</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanosis - radiotherapy</topic><topic>Melanosis - therapy</topic><topic>Middle Aged</topic><topic>Optical Devices</topic><topic>Optics</topic><topic>Original Article</topic><topic>Patient Satisfaction</topic><topic>Patients</topic><topic>Photonics</topic><topic>Quantum Optics</topic><topic>Single-Blind Method</topic><topic>Skin diseases</topic><topic>Therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lai, Dihui</creatorcontrib><creatorcontrib>Cheng, Shaowei</creatorcontrib><creatorcontrib>Zhou, Shaona</creatorcontrib><creatorcontrib>Hao, Jianchun</creatorcontrib><creatorcontrib>Chen, Hongguang</creatorcontrib><creatorcontrib>Jia, Kang</creatorcontrib><creatorcontrib>Liu, Hongmei</creatorcontrib><creatorcontrib>Cui, Yong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Electronics & Communications Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Lasers in medical science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lai, Dihui</au><au>Cheng, Shaowei</au><au>Zhou, Shaona</au><au>Hao, Jianchun</au><au>Chen, Hongguang</au><au>Jia, Kang</au><au>Liu, Hongmei</au><au>Cui, Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>755-nm picosecond laser plus topical 20% azelaic acid compared to topical 20% azelaic acid alone for the treatment of melasma: a randomized, split-face and controlled trial</atitle><jtitle>Lasers in medical science</jtitle><stitle>Lasers Med Sci</stitle><addtitle>Lasers Med Sci</addtitle><date>2024-04-24</date><risdate>2024</risdate><volume>39</volume><issue>1</issue><spage>113</spage><epage>113</epage><pages>113-113</pages><artnum>113</artnum><issn>1435-604X</issn><issn>0268-8921</issn><eissn>1435-604X</eissn><abstract>Purpose: Melasma remains a refractory skin condition that needs to be actively explored. Azelaic acid has been used for decades as a topical agent to improve melasma through multiple mechanisms, however, there is a lack of research on its combination with laser therapy. This study evaluated the effectiveness of isolated treatment with topical 20% azelaic acid and its combination with 755-nm picosecond laser in facial melasma patients. Methods: A randomized, evaluator-blinded, controlled study was conducted on 30 subjects with facial melasma in a single center from October 2021 to April 2022. All subjects received topical 20% azelaic acid cream (AA) for 24 weeks, and after 4 weeks, a hemiface was randomly assigned to receive 755-nm picosecond (PS) laser therapy once every 4 weeks for 3 treatments. Treatment efficacy was determined by mMASI score evaluations, dermoscopic assessment, reflectance confocal microscopy (RCM) assessments and patient’s satisfaction assessments (PSA). Results: Treatment with 20% azelaic acid, with or without picosecond laser therapy, significantly reduced the hemi-mMASI score (
P
< 0.0001) and resulted in higher patient satisfaction. Improvements in dermoscopic and RCM assessments were observed in both sides of the face over time, with no difference between the two sides. RCM exhibited better dentritic cell improvement in the combined treatment side. No patients had serious adverse effects at the end of treatment or during the follow-up period. Conclusion: The additional use of picosecond laser therapy showed no clinical difference except for subtle differences detected by RCM assessments.
The study was registered in the Chinese Clinical Trial Registry (ChiCTR2100051294; 18 September 2021).</abstract><cop>London</cop><pub>Springer London</pub><pmid>38656631</pmid><doi>10.1007/s10103-024-04052-9</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1435-604X |
| ispartof | Lasers in medical science, 2024-04, Vol.39 (1), p.113-113, Article 113 |
| issn | 1435-604X 0268-8921 1435-604X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3046511320 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Acids Administration, Topical Adult Assessments Combined Modality Therapy Combined treatment Confocal microscopy Dentistry Dermatologic Agents - administration & dosage Dermatologic Agents - therapeutic use Dicarboxylic Acids - administration & dosage Dicarboxylic Acids - therapeutic use Female Humans Lasers Lasers, Solid-State - therapeutic use Low-Level Light Therapy - methods Male Medicine Medicine & Public Health Melanosis - radiotherapy Melanosis - therapy Middle Aged Optical Devices Optics Original Article Patient Satisfaction Patients Photonics Quantum Optics Single-Blind Method Skin diseases Therapy Treatment Outcome |
| title | 755-nm picosecond laser plus topical 20% azelaic acid compared to topical 20% azelaic acid alone for the treatment of melasma: a randomized, split-face and controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A25%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=755-nm%20picosecond%20laser%20plus%20topical%2020%25%20azelaic%20acid%20compared%20to%20topical%2020%25%20azelaic%20acid%20alone%20for%20the%20treatment%20of%20melasma:%20a%20randomized,%20split-face%20and%20controlled%20trial&rft.jtitle=Lasers%20in%20medical%20science&rft.au=Lai,%20Dihui&rft.date=2024-04-24&rft.volume=39&rft.issue=1&rft.spage=113&rft.epage=113&rft.pages=113-113&rft.artnum=113&rft.issn=1435-604X&rft.eissn=1435-604X&rft_id=info:doi/10.1007/s10103-024-04052-9&rft_dat=%3Cproquest_cross%3E3046511320%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3046721661&rft_id=info:pmid/38656631&rfr_iscdi=true |